Medicine and Health

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

S. Peters, S. M. Gadgeel, et al.

This phase 2/3 BFAST trial demonstrated that entrectinib provides a remarkable confirmed objective response rate of 81.5% in treatment-naive patients with ROS1-positive NSCLC identified through liquid biopsies. Backed by the authors, these results advocate for the crucial role of liquid biopsies in clinical decision-making for advanced NSCLC.

00:00

Playback language: English

Index

Abstract

This phase 2/3 BFAST trial (NCT03178552) evaluated entrectinib in treatment-naive patients with ROS1-positive NSCLC identified solely by liquid biopsies. The trial met its primary endpoint, demonstrating a confirmed objective response rate (ORR) of 81.5% (95% CI: 68.6–90.8), consistent with results from a tissue-based analysis of entrectinib. The safety profile was consistent with previous reports. These findings support the use of liquid biopsies for clinical decision-making in advanced NSCLC.

Publisher

Nature Medicine

Published On

Jul 01, 2024

Authors

Solange Peters, Shirish M. Gadgeel, Tony Mok, Ernest Nadal, Saadettin Kilickap, Aurélie Swalduz, Jacques Cadranel, Shunichi Sugawara, Chao-Hua Chiu, Chong-Jen Yu, Mor Moskovitz, Tomohiro Tanaka, Rhea Nersesian, Sarah M. Shagan, Margaret Maclennan, Michael Mathisen, Vijay Bhagawati-Prasad, Cheick Diarra, Zoe June Assaf, Venice Archer, Rafal Dziadziuszko

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

B. Besse, E. Pons-tostivint, et al.

Medicine and Health

Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

M. Schuler, K. Cuppens, et al.

Medicine and Health

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial

T. Sonoda, Y. Umeda, et al.

Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

K. Shitara, Y. Bang, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny